Comment on “Assessment of Liver Stiffness in Pediatric Fontan Patients Using Transient Elastography”

Xue, Xiulan; Cai, Shaohang

doi:10.1155/2016/9343960

Cited by 24 publications

(17 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Pretreatment HBsAg, viral load and ALT levels were highlighted to predict post-treatment response of IFN therapy. For CHB patients with pretreatment high ALT level, low viral load and low HBsAg level, treatment with IFN leads to better clinical outcomes [25][26][27][28]. Consistent with previous studies, in our study, we found that baseline ALT >4×ULN, HBV DNA <2×106 IU/mL and HBsAg <25000 IU/mL were significantly associated with EOT HBsAg ≤10 IU/mL.…”

Section: Discussionsupporting

confidence: 90%

HBsAg quantification predicts off-treatment response to interferon in chronic hepatitis B patients：A retrospective study of 250 cases

Luo

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: For chronic hepatitis B (CHB) patients without willingness to extend the routine duration of interferon (IFN) therapy, it is important to identify patients who will benefit from treatment cessation. Hepatitis B surface antigen (HBsAg) quantification is recommended for management of IFN therapy. At present, the understanding on end-of-treatment (EOT) HBsAg level predicting post-treatment response to IFN is still finite. Methods: Patients with CHB infection and treated with IFN-based therapy during the period from December 2010 to December 2017 at Nanfang Hospital were enrolled in this study. Serum HBsAg levels at EOT were measured to evaluate the associations between EOT HBsAg levels (Group 1, HBsAg >0.05 and ≤10 IU/mL; Group 2, HBsAg >10 and ≤200 IU/mL; Group 3, HBsAg >200 IU/mL) with post-treatment HBsAg loss. Chi-squared, t-test, ,Kaplan-Meier analysis, Cox regression analysis, and Multivariate Logistic regression analysis were used to analyse and evaluate differences between the there groups. Results: The cumulative HBsAg loss rates 5 years after treatment in Group 1-3 were 30.4% (17/56), 9.8%(4/41) and 0%(0/153) (p<0.001). An EOT HBsAg level of >10 IU/mL showed relatively high negative predictive value (NPV) of up to 97.9% for HBsAg loss. Low baseline HBsAg level <25000 IU/mL, on-treatment HBsAg decline >1 log10IU/mL at week 24 and EOT HBsAg level ≤10 IU/mL were found significantly associated with HBsAg loss. A total of 6 patients have achieved HBsAg loss at EOT and 17 patients with EOT HBsAg level ≤10 IU/mL have achieved post-treatment HBsAg loss. Baseline characteristics, dynamic changes of on-treatment HBsAg and duration of IFN therapy were balanced across patients with EOT or post-treatment HBsAg loss. Conclusion: EOT HBsAg level can serve as a monitoring indicator for IFN therapy. EOT HBsAg level ≤10 IU/mL was found to lead to high rate of post-treatment HBsAg loss. For patients without willingness to extend IFN treatment, off-treatment follow-up could be considered when HBsAg level decreased to ≤10 IU/mL.

show abstract

Section: Discussionsupporting

confidence: 90%

HBsAg quantification predicts off-treatment response to interferon in chronic hepatitis B patients：A retrospective study of 250 cases

Luo

et al. 2020

Preprint

View full text Add to dashboard Cite

show abstract

“…Pretreatment HBsAg, viral load and ALT levels were highlighted to predict post-treatment response of IFN therapy. For CHB patients with pretreatment high ALT level, low viral load and low HBsAg level, treatment with IFN leads to better clinical outcomes [24][25][26][27]. Consistent with previous studies, in our study, we found that baseline ALT > 4 × ULN, HBV DNA < 2 × 106 IU/mL and HBsAg < 25,000 IU/mL were significantly associated with EOT HBsAg ≤10 IU/mL.…”

Section: Discussionsupporting

confidence: 90%

HBsAg quantification predicts off-treatment response to interferon in chronic hepatitis B patients: a retrospective study of 250 cases

Luo

et al. 2020

BMC Gastroenterol

View full text Add to dashboard Cite

Background: For chronic hepatitis B (CHB) patients without willingness to extend the routine duration of interferon (IFN) therapy, it is important to identify patients who will benefit from treatment cessation. Hepatitis B surface antigen (HBsAg) quantification is recommended for management of IFN therapy. At present, the understanding on end-of-treatment (EOT) HBsAg level predicting post-treatment response to IFN is still finite. Methods: A total of 2451 non-cirrhosis, HBsAg-postive patients treated with IFN-based therapy during the period from December 2010 to December 2017 at Nanfang Hospital were enrolled in this study. Serum HBsAg levels at EOT were measured to evaluate the associations between EOT HBsAg levels (Group 1, HBsAg > 0.05 and ≤ 10 IU/ mL; Group 2, HBsAg > 10 and ≤ 200 IU/mL; Group 3, HBsAg > 200 IU/mL) with post-treatment HBsAg loss. Chisquared, t-test,,Kaplan-Meier analysis, Cox regression analysis, and Multivariate Logistic regression analysis were used to analyse and evaluate differences between the there groups. Results: The cumulative HBsAg loss rates 5 years after treatment in Group 1-3 were 30.4% (17/56), 9.8%(4/41) and 0%(0/153) (p < 0.001). An EOT HBsAg level of > 10 IU/mL showed relatively high negative predictive value (NPV) of up to 97.9% for HBsAg loss. Low baseline HBsAg level < 25,000 IU/mL, on-treatment HBsAg decline > 1 log10IU/mL at week 24 and EOT HBsAg level ≤ 10 IU/mL were found significantly associated with HBsAg loss. A total of 6 patients have achieved HBsAg loss at EOT and 17 patients with EOT HBsAg level ≤ 10 IU/mL have achieved posttreatment HBsAg loss. Baseline characteristics, dynamic changes of on-treatment HBsAg and duration of IFN therapy were balanced across patients with EOT or post-treatment HBsAg loss. Conclusion: EOT HBsAg level can serve as a monitoring indicator for IFN therapy. EOT HBsAg level ≤ 10 IU/mL was found to lead to high rate of post-treatment HBsAg loss. For patients without willingness to extend IFN treatment, off-treatment follow-up could be considered when HBsAg level decreased to ≤10 IU/mL.

show abstract

“…An estimated 240 million individuals worldwide have CHB (1). Although the clinical management of HBV infection and CHB, including anti-viral therapy, have been widely established, CHB infection remains one of the major etiologies of liver fibrosis and cirrhosis (17)(18)(19)(20). Cirrhosis is characterized by diffuse fibrosis and liver tissue abnormalities, including hepatocyte necrosis and regenerative liver nodules (21).…”

Section: Discussionmentioning

confidence: 99%

Association between abdominal obesity and liver steatosis and fibrosis among patients with chronic hepatitis B measured by Fibroscan

Sun

et al. 2019

Exp Ther Med

View full text Add to dashboard Cite

Comment on “Assessment of Liver Stiffness in Pediatric Fontan Patients Using Transient Elastography”

Cited by 24 publications

References 6 publications

HBsAg quantification predicts off-treatment response to interferon in chronic hepatitis B patients：A retrospective study of 250 cases

HBsAg quantification predicts off-treatment response to interferon in chronic hepatitis B patients：A retrospective study of 250 cases

HBsAg quantification predicts off-treatment response to interferon in chronic hepatitis B patients: a retrospective study of 250 cases

Association between abdominal obesity and liver steatosis and fibrosis among patients with chronic hepatitis B measured by Fibroscan

Contact Info

Product

Resources

About